No Data
No Data
GHIT-backed Innovation Achieves Landmark: New Treatment Option for Schistosomiasis Reaches Preschool-Aged Children
Merck & Co. (MRK): One of the Best Psychedelic Stocks to Buy in 2025
Measles Outbreak in Texas Leads to 159 Cases
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
Live Stock News: -2.8% GDP, Trade War Sends Market Lower, Tesla Sales Punished
Merck (MRK.US) plans to include the methylphenidate micro tablets for priority review by the CDE, categorized as a new drug for children.
Lai Temo Wei is a new type of non-nucleoside cytomegalovirus (CMV) inhibitor, and the tablet and injection forms of this product have previously been approved for sale in China.